Observational analysis shows PD-L1 expression and EGFR mutation types affect survival in patients with non-small-cell lung cancer, indicating potential for targeted therapy.
Key Points
Patients with EGFR mutations and PD-L1 positivity had better survival outcomes, with median overall survival of 51 months following TKI therapy.
Around 48.3% of patients exhibited PD-L1 positivity, highlighting its relevance as a biomarker in treatment strategies and outcomes.
Observational analysis utilizing next-generation sequencing assessed mutations and PD-L1 status in 176 cases of non-small-cell lung cancer, confirming subtype variability.
Links between EGFR mutation types and PD-L1 expression stress the importance of integrating molecular profiles into therapeutic decisions.